巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    ARCA biopharma

    ABIO
    2.470
    0.070
    2.92%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・ARCA biopharma - 延遲價格・最後更新於 12/08 9:30
    最高位
    2.470
    最低位
    2.390
    開市價
    --
    前收市價
    2.400
    成交量(千)
    0.63
    成交額(百萬)
    0.01
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    35.59
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    3.170 - 1.710
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    ARCA biopharma
    證券代碼
    ABIO.US
    所屬板塊
    Biotechnology
    公司業務
    ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
    發行量
    14410143
    公司總部
    10170 Church Ranch Way, Suite 100
    公司網址
    http://www.arcabiopharma.com
    公司電郵
    ir@arcobiopharma.com
    公司電話
    +1 720 940-2200
    暫無內容

    關於

    ARCA biopharma(ABIO.US)所屬的行業板塊為Biotechnology。
    ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
    詳細公司背景可參考: http://www.arcabiopharma.com